NiKang Therapeutics Inc.

5 articles with NiKang Therapeutics Inc.

• NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China

  5/3/2022

  NiKang Therapeutics Inc. and Hansoh Pharmaceutical Group Company Limited today announced an exclusive collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.

• NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022

  4/8/2022

  NiKang Therapeutics Inc. today announced presentation of preclinical data investigating NKT2152’s mechanism of action, in vivo pharmacokinetic and pharmacodynamic profile, and anti-tumor effect in multiple xenograft models including ccRCC and hepatocellular carcinoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

  1/5/2022

  NiKang Therapeutics Inc. (“NiKang”),and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate NKT2152.

• NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

  11/30/2021

  NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152.

• NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α)

  11/15/2021

  NiKang Therapeutics Inc. today announced that the first patient has been dosed in a phase 1/2, open-label, dose escalation and expansion study of single agent NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α).